{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T08:47:12Z","timestamp":1765270032357,"version":"3.46.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["endocrinologydiabetes.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["AACE Endocrinology and Diabetes"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.aed.2025.07.004","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:43:16Z","timestamp":1752626596000},"page":"260-264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Giant Prolactinoma: Challenges in Management"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5692-5668","authenticated-orcid":false,"given":"Sapna","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhav","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chheki","family":"Sherpa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.aed.2025.07.004_bib1","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1210\/jcem-71-6-1427","article-title":"Clonal origin of pituitary adenomas","volume":"71","author":"Herman","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.aed.2025.07.004_bib2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/qjmed\/hcs240","article-title":"Macroprolactinoma: a diagnostic and therapeutic update","volume":"106","author":"Iglesias","year":"2013","journal-title":"QJM"},{"issue":"16","key":"10.1016\/j.aed.2025.07.004_bib3","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1001\/jama.2023.5444","article-title":"Diagnosis and management of pituitary adenomas: a review","volume":"329","author":"Tritos","year":"2023","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.aed.2025.07.004_bib4","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3171\/jns.2002.97.2.0299","article-title":"Giant prolactinomas: clinical management and long-term follow up","volume":"97","author":"Shrivastava","year":"2002","journal-title":"J Neurosurg"},{"issue":"6","key":"10.1016\/j.aed.2025.07.004_bib5","first-page":"2247","article-title":"Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients","volume":"85","author":"Colao","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.aed.2025.07.004_bib6","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.aed.2025.07.004_bib7","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/er.2005-9998","article-title":"Advances in the treatment of prolactinomas","volume":"27","author":"Gillam","year":"2006","journal-title":"Endocr Rev"},{"issue":"8","key":"10.1016\/j.aed.2025.07.004_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.arcmed.2023.102883","article-title":"Prolactinomas resistant to dopamine agonists: pathophysiology and treatment","volume":"54","author":"Shimon","year":"2023","journal-title":"Arch Med Res"},{"issue":"12","key":"10.1016\/j.aed.2025.07.004_bib9","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.2174\/1871530323666230511104045","article-title":"Italian guidelines for the management of prolactinomas","volume":"23","author":"Cozzi","year":"2023","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"1","key":"10.1016\/j.aed.2025.07.004_bib10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12902-020-0543-4","article-title":"Predictors of dopamine agonist resistance in prolactinoma patients","volume":"20","author":"Vermeulen","year":"2020","journal-title":"BMC Endocr Disord"},{"issue":"4","key":"10.1016\/j.aed.2025.07.004_bib11","doi-asserted-by":"crossref","first-page":"340","DOI":"10.4158\/EP-2018-0392","article-title":"Management and outcomes of giant prolactinoma: a series of 71 patients","volume":"25","author":"Hamidi","year":"2019","journal-title":"Endocr Pract"},{"issue":"6","key":"10.1016\/j.aed.2025.07.004_bib12","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1210\/jc.2013-1249","article-title":"The prevalence and natural history of pituitary hemorrhage in prolactinoma","volume":"98","author":"Sarwar","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.aed.2025.07.004_bib13","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.jocn.2013.02.027","article-title":"Pituitary apoplexy associated with cabergoline therapy","volume":"20","author":"Chng","year":"2013","journal-title":"J Clin Neurosci"},{"issue":"4","key":"10.1016\/j.aed.2025.07.004_bib14","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/cen.12242","article-title":"Giant prolactinomas: the therapeutic approach","volume":"79","author":"Moraes","year":"2013","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["AACE Endocrinology and Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050915725000608?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050915725000608?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T08:43:20Z","timestamp":1765269800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050915725000608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S3050915725000608"],"URL":"https:\/\/doi.org\/10.1016\/j.aed.2025.07.004","relation":{},"ISSN":["3050-9157"],"issn-type":[{"type":"print","value":"3050-9157"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Giant Prolactinoma: Challenges in Management","name":"articletitle","label":"Article Title"},{"value":"AACE Endocrinology and Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aed.2025.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Association of Clinical Endocrinology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}